Department of Hematology, Hematological Research Center, The Second Affiliated Hospital of Anhui Medical University, Hefei, Anhui, China.
Department of Laboratory, Fuyang People's Hospital, Fuyang, China.
Clin Exp Med. 2024 Jan 30;24(1):28. doi: 10.1007/s10238-023-01272-1.
Serine/arginine repetitive matrix 2 (SRRM2) has been implicated in tumorigenesis, cancer development, and drug resistance through aberrant splicing; however, its correlation with multiple myeloma (MM) has not been reported. We investigated the potential of SRRM2 as a biomarker and immunotherapeutic target in MM by examining its expression in MM cells using flow cytometry. Our study included 95 patients with plasma cell disease, including 80 MM cases, and we detected SRRM2 expression on plasma cells and normal blood cells to analyze its relationship with clinical profiles. We found widespread positive expression of SRRM2 on plasma cells with little expression on normal blood cells, and its expression on abnormal plasma cells was higher than that on normal plasma cells. Comparative analysis with clinical data suggests that SRRM2 expression on plasma cells correlates with MM treatment response. MM patients with high SRRM2 expression had higher levels of serum β2-mg and LDH, ISS staging, and plasma cell infiltration, as well as high-risk mSMART 3.0 stratification and cytogenetic abnormalities, particularly 1q21 amplification. In patients with previous MM, high SRRM2 expression on plasma cells was associated with higher plasma cell infiltration, high-risk mSMART 3.0 risk stratification, cytogenetic abnormalities, more relapses, and fewer autologous stem cell transplant treatments. In summary, SRRM2 may serve as a novel biomarker and immunotherapeutic target for MM. Its expression level on plasma cells can help in risk stratification of MM and monitoring of treatment response.
丝氨酸/精氨酸重复矩阵 2（SRRM2）通过异常剪接参与肿瘤发生、癌症发展和耐药性；然而，其与多发性骨髓瘤（MM）的相关性尚未报道。我们通过流式细胞术检查 MM 细胞中 SRRM2 的表达，研究了其作为 MM 生物标志物和免疫治疗靶标的潜力。我们的研究包括 95 例浆细胞疾病患者，其中 80 例为 MM 病例，我们检测了浆细胞和正常血细胞上的 SRRM2 表达，以分析其与临床特征的关系。我们发现浆细胞上广泛存在 SRRM2 的阳性表达，而正常血细胞上的表达很少，异常浆细胞上的表达高于正常浆细胞。与临床数据的比较分析表明，浆细胞上 SRRM2 的表达与 MM 治疗反应相关。SRRM2 表达水平高的 MM 患者血清β2-mg 和 LDH 水平较高，ISS 分期较高，浆细胞浸润较高，高危 mSMART 3.0 分层和细胞遗传学异常较高，特别是 1q21 扩增。在既往 MM 患者中，浆细胞上高 SRRM2 表达与更高的浆细胞浸润、高危 mSMART 3.0 风险分层、细胞遗传学异常、更多复发和更少自体干细胞移植治疗相关。总之，SRRM2 可能成为 MM 的一种新的生物标志物和免疫治疗靶点。其在浆细胞上的表达水平有助于 MM 的风险分层和治疗反应的监测。
